

THRU ONLINE FILING

April 30, 2021

BSE Ltd.
Phiroze Jeejeebhoy Towers
Dalal Street
Mumbai 400 023
Scrip Code – 524494

National Stock Exchange India Limited,
Exchange Plaza, C-1, Block-G,
Bandra Kurla Complex, Bandra – (East).
Mumbai-400051.
Scrip Code : IPCALAB

Dear Sirs,

Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.


This is to inform you that the Company has subscribed to partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP).

The disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Clause A(1) of Part A, Schedule III of the aforesaid regulations, is attached as per "**Annexure A**".

This is for your information and dissemination.

Thanking you

Yours faithfully
For Ipca Laboratories Limited



Harish P. Kamath
Corporate Counsel & Company Secretary

Encl: a/a

Ipca Laboratories Ltd.
www.ipca.com

Annexure A

Disclosure pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 under Clause A(1) of Part A, Schedule III of the aforesaid regulations on subscription of partnership interest in ABCD Technologies LLP (to be renamed as IndoHealth Services LLP) by the Company.

a) Name of the target entity, details in brief such as size, turnover etc.:	i) Name of the Target entity: ABCD Technologies LLP (to be renamed as IndoHealth Services LLP), herein after referred to as the Target entity. ii) Details of Target entity: The Target entity is a limited liability partnership ('LLP') that has various partners. The Target entity will, through its investment entities, engage in the objective of digitizing healthcare infrastructure in India.
b) Whether the acquisition would fall within related party transaction(s) and whether the promoter/promoter group/group companies have any interest in the entity being acquired? If yes, nature of interest and details thereof and whether the same is done at "Arms-length";	No.
c) Industry to which the entity being acquired belongs;	Healthcare services.
d) Objects and effects of acquisition (including but not limited to, disclosure of reasons for acquisition of target entity, if its business is outside the main line of business of the listed entity;	Initiative with an objective to facilitate, enable and promote efficiency and Good Distribution Practices ('GDP') including digitizing healthcare infrastructure in India, inter alia, in support of the National Digital Health Mission of Government of India ('Business').
e) Brief details of any governmental or regulatory approvals required for the acquisition;	None.
f) Indicative time period for completion of the acquisition;	April 30, 2021.
g) Nature of consideration – whether cash consideration or share swap and details of the same;	Cash infusion as capital contribution.



Ipca Laboratories Ltd.
www.ipca.com

h) Cost of acquisition or the price at which the shares are acquired;	Rs. 25 crores.
i) Percentage of shareholding / control acquired and/or number of shares acquired;	4.03% share of profit/ loss in the Target entity.
j) Brief background about the entity acquired in terms of products/line of business acquired, date of incorporation, history of last 3 years turnover, country in which the acquired entity has presence and any other significant information (in brief);	The Target entity has been incorporated on 10th February, 2021. The Target entity through its investments in DigiHealth Technologies LLP, Phamarack Technologies Private Limited, Trikaal Mediinfotech Private Limited and AIOCD Pharnasofttech Awacs Private Limited, aims to achieve the objectives as per clause (d) above.

